WO2020101596A3 - Composition de capsule comprenant du sunitinib - Google Patents

Composition de capsule comprenant du sunitinib Download PDF

Info

Publication number
WO2020101596A3
WO2020101596A3 PCT/TR2019/050579 TR2019050579W WO2020101596A3 WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3 TR 2019050579 W TR2019050579 W TR 2019050579W WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3
Authority
WO
WIPO (PCT)
Prior art keywords
sunitinib
capsule composition
capsule
composition
present
Prior art date
Application number
PCT/TR2019/050579
Other languages
English (en)
Other versions
WO2020101596A2 (fr
Inventor
Ali Turkyilmaz
Yuksel TOPALOGLU
Ali Ihsan SECKIN
Irem Yenice
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020101596A2 publication Critical patent/WO2020101596A2/fr
Publication of WO2020101596A3 publication Critical patent/WO2020101596A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une capsule comprenant du sunitinib et au moins un liant. La présente invention concerne en outre un procédé de préparation de ladite composition.
PCT/TR2019/050579 2018-08-10 2019-07-16 Composition de capsule comprenant du sunitinib WO2020101596A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201811687 2018-08-10
TR2018/11687 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020101596A2 WO2020101596A2 (fr) 2020-05-22
WO2020101596A3 true WO2020101596A3 (fr) 2020-07-09

Family

ID=70730567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050579 WO2020101596A2 (fr) 2018-08-10 2019-07-16 Composition de capsule comprenant du sunitinib

Country Status (1)

Country Link
WO (1) WO2020101596A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113440495B (zh) * 2021-07-14 2022-07-12 北京鑫开元医药科技有限公司 苹果酸舒尼替尼胶囊及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
CN105434399A (zh) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 一种肾细胞癌治疗药物舒尼替尼-PLGA/Fe3O4复合微球及其制备方法
WO2017181187A1 (fr) * 2016-04-15 2017-10-19 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (fr) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
CN105434399A (zh) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 一种肾细胞癌治疗药物舒尼替尼-PLGA/Fe3O4复合微球及其制备方法
WO2017181187A1 (fr) * 2016-04-15 2017-10-19 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (fr) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i

Also Published As

Publication number Publication date
WO2020101596A2 (fr) 2020-05-22

Similar Documents

Publication Publication Date Title
EP3875458A4 (fr) Composé de type diphényle, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et ses applications
WO2018109174A3 (fr) Anticorps anti-il-11
WO2020039321A3 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
WO2019020602A3 (fr) Luminophore et composition
EP4248965A3 (fr) Composés, compositions et procédés
WO2018109170A3 (fr) Anticorps il-11ra
EP3923935A4 (fr) Composés, compositions et procédés
MX2020014013A (es) Composicion edulcorante en polvo y metodo para su preparacion.
EP3924341A4 (fr) Composés, compositions et procédés
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
MX2019001121A (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
WO2018101663A3 (fr) Composition pour l'élimination de tissu biologique et procédé d'élimination de tissu biologique l'utilisant
WO2018127612A3 (fr) Compositions comprenant un extrait de plante lespedeza
WO2020131586A3 (fr) Méthodes d'identification de néo-antigènes
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP3873911A4 (fr) Composés, compositions et procédés de modulation de l'activité de cdk9
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
EP3670511A4 (fr) Composé de tétrahydroprotoberbérine, son procédé de préparation, ses utilisations et composition pharmaceutique
EP3950006A4 (fr) Composé, méthode et composition pharmaceutique pour normalisation de l'expression du dux4
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
EP3757137A4 (fr) Dérivé de p-boronophénylalanine ainsi que composition contenant celui-ci, et kit destiné à la fabrication de ceux-ci
EP3953348A4 (fr) Composés, compositions et procédés
AU2018279184A1 (en) Anti-TrkB antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2